Temozolomide in advanced malignant melanoma with small brain metastases: Can we withhold cranial irradiation?

Cancer

Volumn 109, Issue 2, 2007, Pages 306-312

  Boogerd, Willem ^a   De Gast, Gijsbert C ^a   Dalesio, Otilia ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Brain metastasis; Melanoma; Radiotherapy; Temozolomide

Indexed keywords

ALPHA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; FEASIBILITY STUDY; FEMALE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKULL IRRADIATION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CRANIAL IRRADIATION; DACARBAZINE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33846205132     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22411     Document Type: Article

References (30)

1. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11-20.
2. Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer. 1984;53:2550-2552.
3. Amer MH, Al Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42:660-668.
4. Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93:9-18.
5. Radbill AE, Fiveash JF, Falkenberg ET, et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer. 2004;101:825-833.
6. Manon R, O'Neill A, Knisely J, et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol. 2005;23:8870-8876.
7. Retsas S, Gershuny AR. Central nervous system involvement in malignant melanoma. Cancer. 1988;61:1926-1934.
8. Choi KN, Withers HR, Rotman M. Intracranial metastases from melanoma. Clinical features and treatment by accelerated fractionation. Cancer. 1985;56:1-9.
9. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293-1300.
10. Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol. 1983;1:313-317.
11. Middleton MR, Grob JJ, Aaronson N, et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
12. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751.
13. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a Phase II study. J Clin Oncol. 2004;22:2101-2107.
14. De Gast GC, Batchelor D, Kersten MJ, et al. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. Br J Cancer. 2003;88:175-180.
15. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-751.
16. Morris SL, Low SH, A'Hern RP, et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer. 2004;91:829-833.
17. Margolin K, Atkins B, Thompson A, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a Phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002;128:214-218.
18. Brocker EB, Bohndorf W, Kampgen E, et al. Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study. Melanoma Res. 1996;6:399-401.
19. Ulrich J, Gademann G, Gollnick H. Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation. J Neurooncol. 1999;43:173-178.
20. Hwu WJ, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a Phase II study. Cancer. 2005;103:2590-2597.
21. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a Phase III study. J Clin Oncol. 2004;22:1118-1125.
22. Calabresi F, Aapro M, Becquart D, et al. Multicenter Phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol. 1991;2:377-378.
23. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66:1873-1878.
24. Kleeberg UR, Engel E, Israels P, et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre Phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res. 1995;5:195-200.
25. Fletcher WS, Daniels DS, Sondak VK, et al. Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. A Southwest Oncology Group study. Am J Clin Oncol. 1993;16:359-362.
26. Bafaloukos D, Gogas H, Georgoulias V, et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a Phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol. 2002;20:420-425.
27. Danson S, Lorigan P, Arance A, et al. Randomized Phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol. 2003;21:2551-2557.
28. Hasegawa H, Ushio Y, Hayakawa T, Yamada K, Mogami H. Changes of the blood-brain barrier in experimental metastatic brain tumors. J Neurosurg. 1983;59:304-310.
29. Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002;12:175-178.
30. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (Baltimore). 1985;64:16-35.